- Home
- AEON vs KLTO Comparison
AEON vs KLTO Comparison
Compare AEON & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- KLTO
- Stock Information
- Founded
- AEON N/A
- KLTO 2019
- Country
- AEON United States
- KLTO United States
- Employees
- AEON N/A
- KLTO N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- KLTO
- Sector
- AEON Health Care
- KLTO
- Exchange
- AEON Nasdaq
- KLTO NYSE
- Market Cap
- AEON 4.2M
- KLTO 5.0M
- IPO Year
- AEON N/A
- KLTO N/A
- Fundamental
- Price
- AEON $0.46
- KLTO $0.16
- Analyst Decision
- AEON Strong Buy
- KLTO
- Analyst Count
- AEON 1
- KLTO 0
- Target Price
- AEON $360.00
- KLTO N/A
- AVG Volume (30 Days)
- AEON 465.0K
- KLTO 152.3K
- Earning Date
- AEON 05-13-2025
- KLTO 05-15-2025
- Dividend Yield
- AEON N/A
- KLTO N/A
- EPS Growth
- AEON N/A
- KLTO N/A
- EPS
- AEON 72.93
- KLTO N/A
- Revenue
- AEON N/A
- KLTO N/A
- Revenue This Year
- AEON N/A
- KLTO N/A
- Revenue Next Year
- AEON N/A
- KLTO N/A
- P/E Ratio
- AEON $0.01
- KLTO N/A
- Revenue Growth
- AEON N/A
- KLTO N/A
- 52 Week Low
- AEON $0.38
- KLTO $0.11
- 52 Week High
- AEON $402.48
- KLTO $13.10
- Technical
- Relative Strength Index (RSI)
- AEON 26.87
- KLTO N/A
- Support Level
- AEON $0.38
- KLTO N/A
- Resistance Level
- AEON $0.43
- KLTO N/A
- Average True Range (ATR)
- AEON 0.04
- KLTO 0.00
- MACD
- AEON 0.20
- KLTO 0.00
- Stochastic Oscillator
- AEON 56.29
- KLTO 0.00
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.